{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+3&page=47",
    "query": {
      "intervention": "Dose Level 3",
      "page": 47
    },
    "page_size": 10
  },
  "pagination": {
    "page": 47,
    "page_size": 10,
    "total_count": 17839,
    "total_pages": 1784,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+3&page=48&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+3&page=46&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T12:39:06.616Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04165772",
      "title": "Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rectal Adenocarcinoma",
        "Clinical Stage: Stage II (T3-4, N-)",
        "Stage III (Any T, N+)",
        "Solid Tumor",
        "Solid Tumor, Adult",
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "TSR-042 or Dostarlimab",
          "type": "DRUG"
        },
        {
          "name": "capecitabine or 5-FU",
          "type": "DRUG"
        },
        {
          "name": "Intensity Modulated Radiation Therapy (IMRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 212,
      "start_date": "2019-12-11",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-18T12:39:06.616Z",
      "location_count": 10,
      "location_summary": "Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04165772"
    },
    {
      "nct_id": "NCT07294677",
      "title": "CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Capivasertib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Blinatumomab",
          "type": "DRUG"
        },
        {
          "name": "Nelarabine",
          "type": "DRUG"
        },
        {
          "name": "mini-hyperCVD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2026-03-17",
      "completion_date": "2032-03",
      "has_results": false,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-11-18T12:39:06.616Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07294677"
    },
    {
      "nct_id": "NCT01280981",
      "title": "A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Menorrhagia"
      ],
      "interventions": [
        {
          "name": "Tranexamic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ferring Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 288,
      "start_date": "2007-04",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2011-07-26",
      "last_synced_at": "2026-11-18T12:39:06.616Z",
      "location_count": 92,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 79 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01280981"
    },
    {
      "nct_id": "NCT01489865",
      "title": "ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "ABT-888",
          "type": "DRUG"
        },
        {
          "name": "mFOLFOX-6",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2011-01-03",
      "completion_date": "2023-12-07",
      "has_results": true,
      "last_update_posted_date": "2025-11-06",
      "last_synced_at": "2026-11-18T12:39:06.616Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01489865"
    },
    {
      "nct_id": "NCT00249964",
      "title": "Combination Paclitaxel, Carboplatin and Temozolomide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Diseases",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Combination Treatment - Cohort 1",
          "type": "DRUG"
        },
        {
          "name": "Combination Treatment - Cohort 2",
          "type": "DRUG"
        },
        {
          "name": "Combination Treatment - Cohort 3",
          "type": "DRUG"
        },
        {
          "name": "Combination Treatment - Cohort 4",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New Mexico Cancer Research Alliance",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2003-11",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2016-01-20",
      "last_synced_at": "2026-11-18T12:39:06.616Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00249964"
    },
    {
      "nct_id": "NCT01384734",
      "title": "HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "BMS-663068 400 mg",
          "type": "DRUG"
        },
        {
          "name": "BMS-663068 800 mg",
          "type": "DRUG"
        },
        {
          "name": "BMS-663068 600 mg",
          "type": "DRUG"
        },
        {
          "name": "BMS-663068 1200 mg",
          "type": "DRUG"
        },
        {
          "name": "Raltegravir 400 mg",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 254,
      "start_date": "2011-07-26",
      "completion_date": "2017-05-12",
      "has_results": true,
      "last_update_posted_date": "2018-11-14",
      "last_synced_at": "2026-11-18T12:39:06.616Z",
      "location_count": 13,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Coral Gables, Florida + 9 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01384734"
    },
    {
      "nct_id": "NCT02715531",
      "title": "A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "5-FU",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 243,
      "start_date": "2016-04-06",
      "completion_date": "2021-05-31",
      "has_results": false,
      "last_update_posted_date": "2021-07-09",
      "last_synced_at": "2026-11-18T12:39:06.616Z",
      "location_count": 12,
      "location_summary": "Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 8 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02715531"
    },
    {
      "nct_id": "NCT07266831",
      "title": "A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Human Immunodeficiency Virus Type 1 (HIV-1) Infection"
      ],
      "interventions": [
        {
          "name": "ISL",
          "type": "DRUG"
        },
        {
          "name": "ULO",
          "type": "DRUG"
        },
        {
          "name": "BIC/FTC/TAF",
          "type": "DRUG"
        },
        {
          "name": "Placebo for BIC/FTC/TAF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to ISL/ULO",
          "type": "DRUG"
        },
        {
          "name": "ISL/ULO",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 570,
      "start_date": "2025-12-18",
      "completion_date": "2031-12-18",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-18T12:39:06.616Z",
      "location_count": 24,
      "location_summary": "Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 20 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "Miami Gardens",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07266831"
    },
    {
      "nct_id": "NCT02184637",
      "title": "A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria, Vivax"
      ],
      "interventions": [
        {
          "name": "Tafenoquine",
          "type": "DRUG"
        },
        {
          "name": "Dihydroartemisinin + Piperaquine tetraphosphate",
          "type": "DRUG"
        },
        {
          "name": "Artemether + Lumefantrine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 120,
      "start_date": "2014-07-31",
      "completion_date": "2015-04-08",
      "has_results": false,
      "last_update_posted_date": "2017-07-13",
      "last_synced_at": "2026-11-18T12:39:06.616Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02184637"
    },
    {
      "nct_id": "NCT01004445",
      "title": "A Study to Determine the Correct Dose of Amikacin Which is Delivered Directly to the Lungs of Ventilated Patients as an Aerosol Via an Investigational Device Called the Pulmonary Delivery Device System (PDDS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pneumonia"
      ],
      "interventions": [
        {
          "name": "Amikacin (BAY41-6551)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2005-05",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2011-04-08",
      "last_synced_at": "2026-11-18T12:39:06.616Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Melbourne, Florida • Albany, New York + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Albany",
          "state": "New York"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01004445"
    }
  ]
}